Compare Apple Inc (AAPL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Summit Therapeutics Inc — how do they compare? Apple Inc trades at $313.4 (market cap $4.56T), while Summit Therapeutics Inc trades at $15.77 (market cap $12.32B). The key difference: Apple Inc is far larger — about 370.1× Summit Therapeutics Inc's market cap, and Apple Inc pays a 0.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAPL | SMMT | |
|---|---|---|
Market Cap | $4.56T | $12.32B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $29.32 |
52-Week Low | $202.38 | $13.05 |
Enterprise Value | $4.58T | $11.74B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $313.28, up 0.2% on the day, with a bullish technical signal and strong support at $309. Recent earnings beats and a 26.91% net margin in 2025 highlight robust profitability. Revenue grew to $416.16B in 2025, with further growth projected to $451.4B in 2026. Positive news includes leading smartphone shipments and institutional buying, though union-busting allegations and potential Q2 2026 earnings miss pose concerns.
Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Strengths include high margins, cash flow generation, and AI opportunities via 2.5B device base. Risks involve competitive pressures, regulatory scrutiny from EU fines, and reliance on iPhone sales. Analyst sentiment is bullish (63% buy ratings), but investors should monitor execution against earnings expectations.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
